Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics
Retained Earnings
Nektar Therapeutics
Retained Earnings Peer Comparison
Competitive Retained Earnings Analysis
Latest Figures & CAGR of Competitors
Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Nektar Therapeutics
NASDAQ:NKTR
|
Retained Earnings
-$3.5B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-7%
|
|
Johnson & Johnson
NYSE:JNJ
|
Retained Earnings
$153.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Retained Earnings
$15.6B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-7%
|
|
Pfizer Inc
NYSE:PFE
|
Retained Earnings
$121.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
Merck & Co Inc
NYSE:MRK
|
Retained Earnings
$56.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
4%
|
|
Eli Lilly and Co
NYSE:LLY
|
Retained Earnings
$12.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
21%
|
CAGR 10-Years
-3%
|
See Also
What is Nektar Therapeutics's Retained Earnings?
Retained Earnings
-3.5B
USD
Based on the financial report for Mar 31, 2024, Nektar Therapeutics's Retained Earnings amounts to -3.5B USD.
What is Nektar Therapeutics's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
-7%
Over the last year, the Retained Earnings growth was -5%. The average annual Retained Earnings growth rates for Nektar Therapeutics have been -13% over the past three years , -18% over the past five years , and -7% over the past ten years .